Loading data for INMB — first visit, this takes a few seconds.
INmune Bio Inc. (INMB)
NasdaqCM: INMB
· Real-Time Price · USD
2.32
+0.16 (7.41%)
At close: Aug 24, 2026, 7:24 PM
The price, the headline numbers and the latest news, in one place.
INmune Bio Inc. (INMB) Stock Price, Analysis & Data
7.41% (1D)
No data available
| Bid | 1.66 |
| Market Cap | 65.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.42M |
| 0.90 | |
| -0.62 | |
| n/a | |
| -4.81 | |
| P/B (ttm) | 3.20 |
| P/S (ttm) | n/a |
| Earnings Date | Oct 29, 2026 |
| Ask | 2.8 |
| Volume | 519,645 |
| Avg. Volume (20D) | 727,956 |
| Open | 2.22 |
| Previous Close | 2.16 |
| Day's Range | 2.19 - 2.34 |
| 52-Week Range | 1.09 - 2.38 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About INMB
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and I...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2019
Employees 21
Stock Exchange NasdaqCM
Ticker Symbol INMB
Website https://www.inmunebio.com
Financial Performance
In 2025, INmune Bio's revenue was 50K, an increase of 257.14% compared to the previous year's 14K. Earnings were -45.93M, an increase of 9.15%.
Financial StatementsEarnings Surprise
INmune Bio has released their quarterly earnings on Aug 6, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.05 exceeds estimates by 0.15, with 85.29% YoY growth.
INmune Bio Inc. is scheduled to release its earnings on Oct 29, 2026, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2